Compare Gilead Sciences, Inc. (GILD) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Prudential PLC — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Gilead Sciences, Inc. is far larger — about 6.3× Prudential PLC's market cap, and Prudential PLC pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Prudential PLC for 119 Days on average.
| GILD | PUK | |
|---|---|---|
Market Cap | $182.40B | $28.84B |
Volume | 4,469,821 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $155.80 | $33.61 |
52-Week Low | $116.74 | $23.54 |
Typical Hold Time | 111 Days | 119 Days |
Enterprise Value | $205.46B | $28.38B |
Dividend Yield | 2.23% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Prudential Public Limited Company (PUK) trades at $23.92, up 1.61% over 24 hours, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $27.39B in 2025 and a net income of $3.98B, with improving profitability margins and a low P/E of 8.4. Recent news highlights strategic shifts, including the sale of its Alexforbes stake and a focus on core markets.
The outlook is mixed: solid fundamentals and analyst 'Moderate Buy' consensus support upside, but technical weakness and earnings misses pose near-term risks. Key opportunities include capital return initiatives and cost savings; risks involve execution of strategic overhaul and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
